Loading…

Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma

The prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2018-06, Vol.13 (6), p.e0198896-e0198896
Main Authors: Shi, Yunpeng, Su, Chang, Hu, Haixia, Yan, He, Li, Wei, Chen, Guohui, Xu, Dahai, Du, Xiaohong, Zhang, Ping
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3
cites cdi_FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3
container_end_page e0198896
container_issue 6
container_start_page e0198896
container_title PloS one
container_volume 13
creator Shi, Yunpeng
Su, Chang
Hu, Haixia
Yan, He
Li, Wei
Chen, Guohui
Xu, Dahai
Du, Xiaohong
Zhang, Ping
description The prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial thyroidectomy. Male patients with PTC or a benign thyroid nodule (BTN) and healthy controls (HCs) were retrospectively included. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of preoperative serum MMP-2 in diagnosing PTC, predicting lymph node metastasis (LNM), and predicting structurally persistent/recurrent disease (SPRD). Multivariate logistic regression and Cox regression were applied to identify independent risk factors for SPRD. The preoperative serum MMP-2 concentration in the PTC group was higher than those in BTN and HC groups. The concentration of postoperative serum MMP-2 decreased in comparison with pre-operation. ROC curves showed that serum MMP-2 could differentially diagnose PTC from BTN at the cutoff value of 86.30 ng/ml with an area under the curve (AUC) of 0.905 and could predict central LNM (CLNM) at the cutoff value of 101.55 ng/ml with an AUC of 0.711. Serum MMP-2 ≥101.55 ng/ml, age ≥45 years, and advanced TNM stage were independent risk factors for CLNM. Patients with SPRD had a higher median MMP-2 level (149.22 ng/ml) than patients without SPRD (104.55 ng/ml). Serum MMP-2 at the cutoff value of 144.04 ng/ml could predict SPRD in PTC patients with an AUC of 0.803. Advanced TNM stage and serum MMP-2 ≥144.04 ng/ml were independent risk factors for SPRD. Patients with serum MMP-2 ≥144.04 ng/ml had a worse clinical outcome than those with MMP-2
doi_str_mv 10.1371/journal.pone.0198896
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2060854536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A547840889</galeid><doaj_id>oai_doaj_org_article_b60110c1510d48ea9ff4c68f5f1eb664</doaj_id><sourcerecordid>A547840889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3</originalsourceid><addsrcrecordid>eNqNkl9v0zAUxSMEYmPwDRBEQkLw0GLHiWO_IE0Tfyp1GmLAq3XrXLceSZzZyUS_Pe6aTQ3aA_KDLft3j32PT5K8pGROWUk_XLnBt1DPO9finFAphOSPkmMqWTbjGWGPD9ZHybMQrggpmOD8aXKUSZlLTsVxsrxEPzTp-fm3WZZCSCHtXI9tb6FOO4-V1b29wbQB_xt9apxPO-hsXYPfpv1m652tUg1e29Y18Dx5YqAO-GKcT5Kfnz_9OPs6W158WZydLme6zFk_MwWwCjOSQSkl7GagnJWaCqCYQyGQ6YJoA5IxCkRQlEyjIEzSkkpt2Enyeq_b1S6o0YigMsKJKPKC8Ugs9kTl4Ep13sYGtsqBVbcbzq8V-N7qGtWKE0qJpgUlVS4QpDG55sIUhuKK8zxqfRxvG1YNVjq646GeiE5PWrtRa3ejOMlotDwKvBsFvLseMPSqsUFjNLFFN9y-m-aUlKyI6Jt_0Ie7G6k1xAZsa1y8V-9E1WmRlyInMQyRmj9AxVFhY3VMjbFxf1LwflIQmR7_9GsYQlCLy-__z178mrJvD9gNQt1vgquH3ro2TMF8D2rvQvBo7k2mRO1Cf-eG2oVejaGPZa8OP-i-6C7l7C8WQfsQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2060854536</pqid></control><display><type>article</type><title>Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Shi, Yunpeng ; Su, Chang ; Hu, Haixia ; Yan, He ; Li, Wei ; Chen, Guohui ; Xu, Dahai ; Du, Xiaohong ; Zhang, Ping</creator><contributor>Ahmad, Aamir</contributor><creatorcontrib>Shi, Yunpeng ; Su, Chang ; Hu, Haixia ; Yan, He ; Li, Wei ; Chen, Guohui ; Xu, Dahai ; Du, Xiaohong ; Zhang, Ping ; Ahmad, Aamir</creatorcontrib><description>The prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial thyroidectomy. Male patients with PTC or a benign thyroid nodule (BTN) and healthy controls (HCs) were retrospectively included. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of preoperative serum MMP-2 in diagnosing PTC, predicting lymph node metastasis (LNM), and predicting structurally persistent/recurrent disease (SPRD). Multivariate logistic regression and Cox regression were applied to identify independent risk factors for SPRD. The preoperative serum MMP-2 concentration in the PTC group was higher than those in BTN and HC groups. The concentration of postoperative serum MMP-2 decreased in comparison with pre-operation. ROC curves showed that serum MMP-2 could differentially diagnose PTC from BTN at the cutoff value of 86.30 ng/ml with an area under the curve (AUC) of 0.905 and could predict central LNM (CLNM) at the cutoff value of 101.55 ng/ml with an AUC of 0.711. Serum MMP-2 ≥101.55 ng/ml, age ≥45 years, and advanced TNM stage were independent risk factors for CLNM. Patients with SPRD had a higher median MMP-2 level (149.22 ng/ml) than patients without SPRD (104.55 ng/ml). Serum MMP-2 at the cutoff value of 144.04 ng/ml could predict SPRD in PTC patients with an AUC of 0.803. Advanced TNM stage and serum MMP-2 ≥144.04 ng/ml were independent risk factors for SPRD. Patients with serum MMP-2 ≥144.04 ng/ml had a worse clinical outcome than those with MMP-2 &lt;144.04 ng/ml. Preoperative serum MMP-2 may serve as a biomarker for diagnosing PTC and a predictive indicator for LNM and SPRD in male patients with PTC.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0198896</identifier><identifier>PMID: 29949618</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Bioindicators ; Biology and Life Sciences ; Biomarkers ; Biomarkers, Tumor - blood ; Blood diseases ; Breast cancer ; Cancer therapies ; Chemotherapy ; Colorectal cancer ; Diagnosis ; Follow-Up Studies ; Gelatinase A ; Health aspects ; Humans ; Identification and classification ; Lymph nodes ; Lymphatic Metastasis ; Lymphatic system ; Male ; Matrix metalloproteinase ; Matrix Metalloproteinase 2 - blood ; Medical diagnosis ; Medical prognosis ; Medicine and Health Sciences ; Metalloproteinase ; Metalloproteins ; Metastases ; Metastasis ; Middle Aged ; Ovarian cancer ; Pancreatic cancer ; Papillary thyroid carcinoma ; Patients ; Prognosis ; Retrospective Studies ; Risk analysis ; Risk factors ; Surgery ; Survival Analysis ; Systematic review ; Thyroid ; Thyroid cancer ; Thyroid Cancer, Papillary - blood ; Thyroid Cancer, Papillary - diagnosis ; Thyroid Cancer, Papillary - pathology ; Thyroid Cancer, Papillary - surgery ; Thyroidectomy ; Tumor markers ; Tumors</subject><ispartof>PloS one, 2018-06, Vol.13 (6), p.e0198896-e0198896</ispartof><rights>COPYRIGHT 2018 Public Library of Science</rights><rights>2018 Shi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Shi et al 2018 Shi et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3</citedby><cites>FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3</cites><orcidid>0000-0002-9029-2523</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2060854536/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2060854536?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29949618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ahmad, Aamir</contributor><creatorcontrib>Shi, Yunpeng</creatorcontrib><creatorcontrib>Su, Chang</creatorcontrib><creatorcontrib>Hu, Haixia</creatorcontrib><creatorcontrib>Yan, He</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Chen, Guohui</creatorcontrib><creatorcontrib>Xu, Dahai</creatorcontrib><creatorcontrib>Du, Xiaohong</creatorcontrib><creatorcontrib>Zhang, Ping</creatorcontrib><title>Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial thyroidectomy. Male patients with PTC or a benign thyroid nodule (BTN) and healthy controls (HCs) were retrospectively included. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of preoperative serum MMP-2 in diagnosing PTC, predicting lymph node metastasis (LNM), and predicting structurally persistent/recurrent disease (SPRD). Multivariate logistic regression and Cox regression were applied to identify independent risk factors for SPRD. The preoperative serum MMP-2 concentration in the PTC group was higher than those in BTN and HC groups. The concentration of postoperative serum MMP-2 decreased in comparison with pre-operation. ROC curves showed that serum MMP-2 could differentially diagnose PTC from BTN at the cutoff value of 86.30 ng/ml with an area under the curve (AUC) of 0.905 and could predict central LNM (CLNM) at the cutoff value of 101.55 ng/ml with an AUC of 0.711. Serum MMP-2 ≥101.55 ng/ml, age ≥45 years, and advanced TNM stage were independent risk factors for CLNM. Patients with SPRD had a higher median MMP-2 level (149.22 ng/ml) than patients without SPRD (104.55 ng/ml). Serum MMP-2 at the cutoff value of 144.04 ng/ml could predict SPRD in PTC patients with an AUC of 0.803. Advanced TNM stage and serum MMP-2 ≥144.04 ng/ml were independent risk factors for SPRD. Patients with serum MMP-2 ≥144.04 ng/ml had a worse clinical outcome than those with MMP-2 &lt;144.04 ng/ml. Preoperative serum MMP-2 may serve as a biomarker for diagnosing PTC and a predictive indicator for LNM and SPRD in male patients with PTC.</description><subject>Adult</subject><subject>Bioindicators</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Blood diseases</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Diagnosis</subject><subject>Follow-Up Studies</subject><subject>Gelatinase A</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Lymph nodes</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 2 - blood</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medicine and Health Sciences</subject><subject>Metalloproteinase</subject><subject>Metalloproteins</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Ovarian cancer</subject><subject>Pancreatic cancer</subject><subject>Papillary thyroid carcinoma</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Surgery</subject><subject>Survival Analysis</subject><subject>Systematic review</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Thyroid Cancer, Papillary - blood</subject><subject>Thyroid Cancer, Papillary - diagnosis</subject><subject>Thyroid Cancer, Papillary - pathology</subject><subject>Thyroid Cancer, Papillary - surgery</subject><subject>Thyroidectomy</subject><subject>Tumor markers</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl9v0zAUxSMEYmPwDRBEQkLw0GLHiWO_IE0Tfyp1GmLAq3XrXLceSZzZyUS_Pe6aTQ3aA_KDLft3j32PT5K8pGROWUk_XLnBt1DPO9finFAphOSPkmMqWTbjGWGPD9ZHybMQrggpmOD8aXKUSZlLTsVxsrxEPzTp-fm3WZZCSCHtXI9tb6FOO4-V1b29wbQB_xt9apxPO-hsXYPfpv1m652tUg1e29Y18Dx5YqAO-GKcT5Kfnz_9OPs6W158WZydLme6zFk_MwWwCjOSQSkl7GagnJWaCqCYQyGQ6YJoA5IxCkRQlEyjIEzSkkpt2Enyeq_b1S6o0YigMsKJKPKC8Ugs9kTl4Ep13sYGtsqBVbcbzq8V-N7qGtWKE0qJpgUlVS4QpDG55sIUhuKK8zxqfRxvG1YNVjq646GeiE5PWrtRa3ejOMlotDwKvBsFvLseMPSqsUFjNLFFN9y-m-aUlKyI6Jt_0Ie7G6k1xAZsa1y8V-9E1WmRlyInMQyRmj9AxVFhY3VMjbFxf1LwflIQmR7_9GsYQlCLy-__z178mrJvD9gNQt1vgquH3ro2TMF8D2rvQvBo7k2mRO1Cf-eG2oVejaGPZa8OP-i-6C7l7C8WQfsQ</recordid><startdate>20180627</startdate><enddate>20180627</enddate><creator>Shi, Yunpeng</creator><creator>Su, Chang</creator><creator>Hu, Haixia</creator><creator>Yan, He</creator><creator>Li, Wei</creator><creator>Chen, Guohui</creator><creator>Xu, Dahai</creator><creator>Du, Xiaohong</creator><creator>Zhang, Ping</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9029-2523</orcidid></search><sort><creationdate>20180627</creationdate><title>Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma</title><author>Shi, Yunpeng ; Su, Chang ; Hu, Haixia ; Yan, He ; Li, Wei ; Chen, Guohui ; Xu, Dahai ; Du, Xiaohong ; Zhang, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Bioindicators</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Blood diseases</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Diagnosis</topic><topic>Follow-Up Studies</topic><topic>Gelatinase A</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Lymph nodes</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 2 - blood</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medicine and Health Sciences</topic><topic>Metalloproteinase</topic><topic>Metalloproteins</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Ovarian cancer</topic><topic>Pancreatic cancer</topic><topic>Papillary thyroid carcinoma</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Surgery</topic><topic>Survival Analysis</topic><topic>Systematic review</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Thyroid Cancer, Papillary - blood</topic><topic>Thyroid Cancer, Papillary - diagnosis</topic><topic>Thyroid Cancer, Papillary - pathology</topic><topic>Thyroid Cancer, Papillary - surgery</topic><topic>Thyroidectomy</topic><topic>Tumor markers</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shi, Yunpeng</creatorcontrib><creatorcontrib>Su, Chang</creatorcontrib><creatorcontrib>Hu, Haixia</creatorcontrib><creatorcontrib>Yan, He</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Chen, Guohui</creatorcontrib><creatorcontrib>Xu, Dahai</creatorcontrib><creatorcontrib>Du, Xiaohong</creatorcontrib><creatorcontrib>Zhang, Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints In Context</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shi, Yunpeng</au><au>Su, Chang</au><au>Hu, Haixia</au><au>Yan, He</au><au>Li, Wei</au><au>Chen, Guohui</au><au>Xu, Dahai</au><au>Du, Xiaohong</au><au>Zhang, Ping</au><au>Ahmad, Aamir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2018-06-27</date><risdate>2018</risdate><volume>13</volume><issue>6</issue><spage>e0198896</spage><epage>e0198896</epage><pages>e0198896-e0198896</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial thyroidectomy. Male patients with PTC or a benign thyroid nodule (BTN) and healthy controls (HCs) were retrospectively included. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of preoperative serum MMP-2 in diagnosing PTC, predicting lymph node metastasis (LNM), and predicting structurally persistent/recurrent disease (SPRD). Multivariate logistic regression and Cox regression were applied to identify independent risk factors for SPRD. The preoperative serum MMP-2 concentration in the PTC group was higher than those in BTN and HC groups. The concentration of postoperative serum MMP-2 decreased in comparison with pre-operation. ROC curves showed that serum MMP-2 could differentially diagnose PTC from BTN at the cutoff value of 86.30 ng/ml with an area under the curve (AUC) of 0.905 and could predict central LNM (CLNM) at the cutoff value of 101.55 ng/ml with an AUC of 0.711. Serum MMP-2 ≥101.55 ng/ml, age ≥45 years, and advanced TNM stage were independent risk factors for CLNM. Patients with SPRD had a higher median MMP-2 level (149.22 ng/ml) than patients without SPRD (104.55 ng/ml). Serum MMP-2 at the cutoff value of 144.04 ng/ml could predict SPRD in PTC patients with an AUC of 0.803. Advanced TNM stage and serum MMP-2 ≥144.04 ng/ml were independent risk factors for SPRD. Patients with serum MMP-2 ≥144.04 ng/ml had a worse clinical outcome than those with MMP-2 &lt;144.04 ng/ml. Preoperative serum MMP-2 may serve as a biomarker for diagnosing PTC and a predictive indicator for LNM and SPRD in male patients with PTC.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>29949618</pmid><doi>10.1371/journal.pone.0198896</doi><tpages>e0198896</tpages><orcidid>https://orcid.org/0000-0002-9029-2523</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2018-06, Vol.13 (6), p.e0198896-e0198896
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2060854536
source Publicly Available Content (ProQuest); PubMed Central
subjects Adult
Bioindicators
Biology and Life Sciences
Biomarkers
Biomarkers, Tumor - blood
Blood diseases
Breast cancer
Cancer therapies
Chemotherapy
Colorectal cancer
Diagnosis
Follow-Up Studies
Gelatinase A
Health aspects
Humans
Identification and classification
Lymph nodes
Lymphatic Metastasis
Lymphatic system
Male
Matrix metalloproteinase
Matrix Metalloproteinase 2 - blood
Medical diagnosis
Medical prognosis
Medicine and Health Sciences
Metalloproteinase
Metalloproteins
Metastases
Metastasis
Middle Aged
Ovarian cancer
Pancreatic cancer
Papillary thyroid carcinoma
Patients
Prognosis
Retrospective Studies
Risk analysis
Risk factors
Surgery
Survival Analysis
Systematic review
Thyroid
Thyroid cancer
Thyroid Cancer, Papillary - blood
Thyroid Cancer, Papillary - diagnosis
Thyroid Cancer, Papillary - pathology
Thyroid Cancer, Papillary - surgery
Thyroidectomy
Tumor markers
Tumors
title Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A28%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20MMP-2%20as%20a%20potential%20predictive%20marker%20for%20papillary%20thyroid%20carcinoma&rft.jtitle=PloS%20one&rft.au=Shi,%20Yunpeng&rft.date=2018-06-27&rft.volume=13&rft.issue=6&rft.spage=e0198896&rft.epage=e0198896&rft.pages=e0198896-e0198896&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0198896&rft_dat=%3Cgale_plos_%3EA547840889%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c743t-f5a3de202a799a202aa1637c18a1e4a58e3c50cfa9331a081e93ce80391719cf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2060854536&rft_id=info:pmid/29949618&rft_galeid=A547840889&rfr_iscdi=true